Drug interactions
Denosumab + Efgartigimod alfa
Severity: Moderate
Denosumab and Efgartigimod alfa: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Efgartigimod blocks the neonatal Fc receptor, which recycles IgG and protects it from degradation. Denosumab is an IgG2 antibody, so its exposure and bone-protective effect could theoretically fall. Clinical data are lacking.
What this interaction means in plain words
Denosumab and Efgartigimod alfa can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Denosumab belongs to Oncology; Efgartigimod alfa belongs to Miscellaneous.
Why it happens
FcRn blockade accelerates IgG catabolism and may lower denosumab concentrations.
What to do
Monitor bone turnover markers and bone density response, and watch for loss of effect such as rising resorption markers. If denosumab is essential long term, consider the timing of efgartigimod cycles or alternative antiresorptives.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Denosumab and Efgartigimod alfa, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Denosumab
- Abatacept + Denosumab Moderate
- Adalimumab + Denosumab Moderate
- Alefacept + Denosumab Moderate
- Alemtuzumab + Denosumab Moderate
- Anakinra + Denosumab Moderate
- Azacitidine + Denosumab Moderate
Other interactions of Efgartigimod alfa
- Adalimumab + Efgartigimod alfa Moderate
- Ado-trastuzumab + Efgartigimod alfa Moderate
- Basiliximab + Efgartigimod alfa Moderate
- Bevacizumab + Efgartigimod alfa Moderate
- Brentuximab + Efgartigimod alfa Moderate
- Efgartigimod alfa + Galcanezumab Moderate
Frequently asked questions
Can I take Denosumab with Efgartigimod alfa?
MediHelp rates the interaction as moderate. Denosumab and Efgartigimod alfa can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Efgartigimod blocks the neonatal Fc receptor, which recycles IgG and protects it from degradation. Denosumab is an IgG2 antibody, so its exposure and bone-protective effect could theoretically fall. Clinical data are lacking.
How serious is the interaction between Denosumab and Efgartigimod alfa?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor bone turnover markers and bone density response, and watch for loss of effect such as rising resorption markers. If denosumab is essential long term, consider the timing of efgartigimod cycles or alternative antiresorptives.
What other medicines interact with Denosumab?
MediHelp also lists interactions of Denosumab with, for example, Abatacept, Adalimumab, Alefacept. The full list is on the Denosumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
